Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-26-015550
Filing Date
2026-02-12
Accepted
2026-02-12 16:01:55
Documents
57
Period of Report
2025-12-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0275848-10q_pluri.htm   iXBRL 10-Q 928230
2 CERTIFICATION ea027584801ex31-1_pluri.htm EX-31.1 11315
3 CERTIFICATION ea027584801ex31-2_pluri.htm EX-31.2 11357
4 CERTIFICATION ea027584801ex32-1_pluri.htm EX-32.1 3893
5 CERTIFICATION ea027584801ex32-2_pluri.htm EX-32.2 4014
  Complete submission text file 0001213900-26-015550.txt   4911715

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE plur-20251231.xsd EX-101.SCH 38052
7 XBRL CALCULATION FILE plur-20251231_cal.xml EX-101.CAL 39572
8 XBRL DEFINITION FILE plur-20251231_def.xml EX-101.DEF 190886
9 XBRL LABEL FILE plur-20251231_lab.xml EX-101.LAB 418549
10 XBRL PRESENTATION FILE plur-20251231_pre.xml EX-101.PRE 222400
60 EXTRACTED XBRL INSTANCE DOCUMENT ea0275848-10q_pluri_htm.xml XML 623494
Mailing Address MATAM ADVANCED TECHNOLOGY PARK BUILDING NO. 5 HAIFA Israel
Business Address MATAM ADVANCED TECHNOLOGY PARK BUILDING NO. 5 HAIFA Israel 972-74-710-7171
Pluri Inc. (Filer) CIK: 0001158780 (see all company filings)

EIN.: 980351734 | State of Incorp.: NV | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 001-31392 | Film No.: 26626044
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)